SAB Biotherapeutics (NASDAQ:SABS) Shares Down 6.7% – Here’s Why

SAB Biotherapeutics, Inc. (NASDAQ:SABS) fell 6.7% on Friday . The company traded as low as $1.82 and last traded at $1.82. 70,909 shares traded hands during trading, a decline of 58% from the average session volume of 168,294 shares. The stock had previously closed at $1.95.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SABS. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69. The stock has a 50 day simple moving average of $3.20 and a 200 day simple moving average of $3.03.

Hedge Funds Weigh In On SAB Biotherapeutics

Large investors have recently bought and sold shares of the stock. Northern Trust Corp bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth approximately $43,000. Geode Capital Management LLC grew its position in shares of SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after buying an additional 12,692 shares during the last quarter. Kovitz Investment Group Partners LLC bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth approximately $52,000. Diadema Partners LP bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth approximately $114,000. Finally, HB Wealth Management LLC grew its position in shares of SAB Biotherapeutics by 118.6% in the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after buying an additional 128,800 shares during the last quarter. 7.82% of the stock is owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.